Literature DB >> 9689741

Brucella melitensis infection in sheep: present and future.

B Garin-Bastuji1, J M Blasco, M Grayon, J M Verger.   

Abstract

Sheep brucellosis, a zoonosis mainly due to B. melitensis (biovar 1, 2 or 3), remains widespread world-wide. Pathologically and epidemiologically, the disease is very similar to B. abortus infection in cattle. The live B. melitensis Rev 1 strain is currently considered as the best vaccine available for the control of sheep brucellosis, especially when used at the standard dose by the conjunctival route. Used exhaustively in whole-flock vaccination programmes, it induces a great decrease in the prevalence in both sheep and human populations. The expensive test-and-slaughter strategy should be restricted to the lowest infected areas. Whenever possible, Brucella spp. should be isolated by culture using adequate selective media from uterine discharges, aborted fetuses, udder secretions or selected tissues, such as lymph nodes, testes or epididymides. Species and biovar identification is routinely based on cultural criteria, on lysis by phages and on simple biochemical and serological tests. The recently developed polymerase chain reaction methods provide additional means of detection and identification. Despite the high degree of DNA homology within the genus Brucella, several methods, including PCR-RFLP and Southern blot, have been developed which allow, to a certain extent, the differentiation between Brucella species and some of their biovars. While several ELISA tests have been developed recently, the rose bengal plate agglutination and complement fixation tests, based on the detection of anti-S-LPS antibody, are still recommended for screening flocks and individuals. However, these tests sometimes lack specificity or sensitivity. For pooled samples, there are no useful tests such as the milk ring test in cattle. The brucellin allergic skin test can be used as a screening or complementary test in unvaccinated flocks, provided that a purified, lipopolysaccharide (LPS)-free and standardized antigen preparation is used.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9689741

Source DB:  PubMed          Journal:  Vet Res        ISSN: 0928-4249            Impact factor:   3.683


  22 in total

1.  Gaps in brucellosis eradication campaign in sheep and goats in Republic of Macedonia: lessons learned.

Authors:  Ivanco Naletoski; Toni Kirandziski; Dine Mitrov; Kiril Krstevski; Igor Dzadzovski; Sinisa Acevski
Journal:  Croat Med J       Date:  2010-08       Impact factor: 1.351

2.  The genome sequence of the facultative intracellular pathogen Brucella melitensis.

Authors:  Vito G DelVecchio; Vinayak Kapatral; Rajendra J Redkar; Guy Patra; Cesar Mujer; Tamara Los; Natalia Ivanova; Iain Anderson; Anamitra Bhattacharyya; Athanasios Lykidis; Gary Reznik; Lynn Jablonski; Niels Larsen; Mark D'Souza; Axel Bernal; Mikhail Mazur; Eugene Goltsman; Eugene Selkov; Philip H Elzer; Sue Hagius; David O'Callaghan; Jean-Jacques Letesson; Robert Haselkorn; Nikos Kyrpides; Ross Overbeek
Journal:  Proc Natl Acad Sci U S A       Date:  2001-12-26       Impact factor: 11.205

3.  Rapid immunofiltration assay based on colloidal gold-protein G conjugate as an alternative screening test for bovine and ovine brucellosis.

Authors:  Oktay Genç; Ozlem Büyüktanır; Nevzat Yurdusev
Journal:  Trop Anim Health Prod       Date:  2011-11-21       Impact factor: 1.559

4.  Use of recombinant BP26 protein in serological diagnosis of Brucella melitensis infection in sheep.

Authors:  A Cloeckaert; S Baucheron; N Vizcaino; M S Zygmunt
Journal:  Clin Diagn Lab Immunol       Date:  2001-07

5.  Epidemiological characteristics of brucellosis in Federation of Bosnia and Herzegovina.

Authors:  Zarema Obradović; Ramiz Velić
Journal:  Croat Med J       Date:  2010-08       Impact factor: 1.351

6.  Selection of protective epitopes for Brucella melitensis by DNA vaccination.

Authors:  Xinghong Yang; Mary Hudson; Nancy Walters; Robert F Bargatze; David W Pascual
Journal:  Infect Immun       Date:  2005-11       Impact factor: 3.441

7.  Characterization of Brucella abortus O-polysaccharide and core lipopolysaccharide mutants and demonstration that a complete core is required for rough vaccines to be efficient against Brucella abortus and Brucella ovis in the mouse model.

Authors:  D Monreal; M J Grilló; D González; C M Marín; M J De Miguel; I López-Goñi; J M Blasco; A Cloeckaert; I Moriyón
Journal:  Infect Immun       Date:  2003-06       Impact factor: 3.441

8.  Brucellosis of ruminants in Bosnia and Herzegovina: disease status, past experiences and initiation of a new surveillance strategy.

Authors:  Sabina Serić-Haracić; Mo Salman; Nihad Fejzić; Semra Cavaljuga
Journal:  Bosn J Basic Med Sci       Date:  2008-02       Impact factor: 3.363

9.  Multicenter study of brucellosis in Egypt.

Authors:  Hassan Samaha; Meshref Al-Rowaily; Ramadan M Khoudair; Hossam M Ashour
Journal:  Emerg Infect Dis       Date:  2008-12       Impact factor: 6.883

10.  Registered Influenza Viral Vector Based Brucella abortus Vaccine for Cattle in Kazakhstan: Age-Wise Safety and Efficacy Studies.

Authors:  Sholpan Ryskeldinova; Nadezhda Zinina; Zhailaubay Kydyrbayev; Bolat Yespembetov; Yerken Kozhamkulov; Dulat Inkarbekov; Nurika Assanzhanova; Aigerim Mailybayeva; Dina Bugybayeva; Makhpal Sarmykova; Berik Khairullin; Kairat Tabynov; Aitbay Bulashev; Batyrbek Aitzhanov; Khairulla Abeuov; Abylay Sansyzbay; Tlektes Yespolov; Gourapura J Renukaradhya; Steven Olsen; Angel Oñate; Kaissar Tabynov
Journal:  Front Cell Infect Microbiol       Date:  2021-07-01       Impact factor: 5.293

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.